Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam
Biotech
Alnylam abandons clinical-stage Type 2 diabetes asset
Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity.
Gabrielle Masson
Oct 31, 2024 10:27am
BridgeBio touts case for acoramidis with post hoc study analysis
Sep 30, 2024 9:37am
BridgeBio’s offshoot GondolaBio launches with $300M
Aug 21, 2024 11:36am
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Oct 26, 2023 8:51am
RNA biotech ADARx hauls in healthy $200M series C
Aug 9, 2023 10:17am
Roche signs onto Alnylam's midstage hypertension med for $310M
Jul 24, 2023 11:00am
